Arjunolic acid

Synonyms: 阿江榄仁酸; 阿酚酸
Arjunolic acid 是一种具有口服活性的多功能生物活性化合物,具有自由基清除活性以及抗真菌和抗细菌活性,可诱导多种癌细胞凋亡,并通过减少活性氧和抑制 NF-κB 激活保护肝细胞免受诱导的氧化应激和凋亡,通过阻断 2 型糖尿病大鼠 TLR-4/MyD88 和经典 Wnt 通路激活来调节胰腺功能障碍,通过小胶质细胞 SIRT1/AMPK/Notch1 信号通路抑制神经炎症并改善抑郁行为,通过恢复肠道菌群组成和抑制 TLR4 信号传导来改善克罗恩病样结肠炎,通过抑制 Wnt3a 介导的巨噬细胞 M2 极化来抑制骨肉瘤进展,并通过 AMPK/mTOR/HO-1 调控的自噬通路改善糖尿病视网膜病变,可用于 2 型糖尿病、器官毒性、抑郁症、克罗恩病、骨肉瘤、糖尿病视网膜病变以及睾丸功能障碍的相关研究。
产品编号: MS-K87214 纯度: 98.17% CAS No.: 465-00-9 分子式: C30H48O5 分子量: 488.70
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Arjunolic acid 是一种具有口服活性的多功能生物活性化合物,具有自由基清除活性以及抗真菌和抗细菌活性,可诱导多种癌细胞凋亡,并通过减少活性氧和抑制 NF-κB 激活保护肝细胞免受诱导的氧化应激和凋亡,通过阻断 2 型糖尿病大鼠 TLR-4/MyD88 和经典 Wnt 通路激活来调节胰腺功能障碍,通过小胶质细胞 SIRT1/AMPK/Notch1 信号通路抑制神经炎症并改善抑郁行为,通过恢复肠道菌群组成和抑制 TLR4 信号传导来改善克罗恩病样结肠炎,通过抑制 Wnt3a 介导的巨噬细胞 M2 极化来抑制骨肉瘤进展,并通过 AMPK/mTOR/HO-1 调控的自噬通路改善糖尿病视网膜病变,可用于 2 型糖尿病、器官毒性、抑郁症、克罗恩病、骨肉瘤、糖尿病视网膜病变以及睾丸功能障碍的相关研究。

生物实验数据

生物活性 Arjunolic acid is an orally active multifunctional bioactive compound that exhibits free radical scavenging activity as well as antifungal and antibacterial activities, induces apoptosis in various cancer cells, protects hepatocytes against induced oxidative stress and apoptosis by reducing reactive oxygen species and inhibiting NF-κB activation, modulates pancreatic dysfunction by blocking TLR-4/MyD88 and canonical Wnt pathway activation in type 2 diabetic rats, inhibits neuroinflammation and ameliorates depressive behavior through the microglial SIRT1/AMPK/Notch1 signaling pathway, ameliorates Crohn's disease-like colitis by restoring gut microbiota composition and inhibiting TLR4 signaling, suppresses osteosarcoma progression by inhibiting Wnt3a-mediated macrophage M2 polarization, and ameliorates diabetic retinopathy through the AMPK/mTOR/HO-1-regulated autophagy pathway, and can be used for research related to type 2 diabetes, organ toxicity, depression, Crohn's disease, osteosarcoma, diabetic retinopathy, and testicular dysfunction.
体外研究
(In Vitro)

Arjunolic acid 可在无细胞体系中通过清除超氧自由基、羟基自由基、过氧化氢和一氧化氮自由基发挥自由基清除剂的作用。
Arjunolic acid (0.5-30 μg/spot) 在体外点样试验中,抑制枯草芽孢杆菌、大肠杆菌和宋内志贺氏菌的生长。
Arjunolic acid (20 μg/mL) 在体外抗真菌试验中以 20 μg/mL 的 IC50 抑制新型隐球菌 的生长。
Arjunolic acid 可通过膜损伤诱导 Dalton 细胞发生 66% 的细胞死亡,诱导 Ehrlich 细胞发生 70% 的细胞死亡。
Arjunolic acid 可抑制 Raji 细胞中由 12-O-十四烷酰佛波醇-13-乙酸酯诱导的 Epstein-Barr virus-EA 激活。
Arjunolic acid (200 μM) 可通过减少活性氧、抑制 NF-κB 激活并阻断内源性和外源性凋亡信号通路,保护小鼠肝细胞免受镉诱导的氧化应激和凋亡性死亡,预防氟化钠诱导的小鼠肝细胞氧化应激与坏死性死亡。
Arjunolic acid (5-20 μM; 1 h) 可促进经 LPS (MS-X54539) 刺激的 BV2 细胞从促炎 M1 表型向抗炎 M2 表型极化,上调细胞中 SIRT1 的表达与活性,激活 AMPK 并抑制 Notch1 的表达。
Arjunolic acid (20-200 μM; 2-24 h) 可在 BV2 小鼠小胶质细胞裂解物中直接结合并稳定 SIRT1 蛋白。
Arjunolic acid (5-40 μM; 48 h) 可通过减少上皮细胞凋亡、提高类器官活力来保护 LPS 诱导的野生型小鼠结肠类器官。
Arjunolic acid (1-100 μg/mL; 24 h) 可呈浓度依赖性降低 Saos-2 和 U-2OS 骨肉瘤细胞的活力。
Arjunolic acid (50 μg/mL; 24 h pre-treatment of M2/M0 macrophages) 处理后的 M2/M0 巨噬细胞可抑制 Saos-2 和 U-2OS 骨肉瘤细胞的增殖、迁移及侵袭能力,诱导其发生 G1 期细胞周期阻滞,并促进这些细胞的凋亡。
Arjunolic acid (50 μg/mL) 可促进 M0 巨噬细胞向促炎型 M1 表型极化。
Arjunolic acid (50 μg/mL; 24 h) 可抑制骨肉瘤细胞诱导的 M0 巨噬细胞向 M2 表型极化,并促进其向 M1 表型极化。
Arjunolic acid (50 μg/mL; 24 h) 可抑制 Wnt3a 介导的 M0 巨噬细胞向 M2 型极化,并促进其向 M1 型极化。
Arjunolic acid (5-10 μM; 24 h, co-treated with H2O2) 可显著提升 H2O2 损伤的 ARPE-19 细胞的细胞活力。
Arjunolic acid (5-10 μM; 24 h, co-treated with H2O2) 可呈剂量依赖性地降低 H2O2 诱导的 ARPE-19 细胞的早期凋亡及总凋亡水平,并使凋亡相关蛋白表达恢复正常。
Arjunolic acid (5-10 μM; 24 h, co-treated with H2O2) 可通过降低活性氧 (ROS) 和丙二醛 (MDA) 水平、提高超氧化物歧化酶 (SOD) 水平,并在 10 μM 剂量下上调血红素氧合酶-1 (HO-1),从而减轻 ARPE-19 细胞的氧化应激。
Arjunolic acid (5-10 μM; 24 h, co-treated with H2O2) 通过 AMPK/mTOR 通路激活抑制 H2O2 诱导的 ARPE-19 细胞自噬。

Real Time qPCR

Cell Line: BV2 mouse microglial cells (LPS-stimulated, pretreated with EX-527 SIRT1 inhibitor)
Concentration: 20 μM
Incubation Time: 1 h pretreatment (after EX-527); 24 h LPS co-exposure
Result: Reversed the arjunolic acid-mediated downregulation of M1 marker (IL-1β, TNF-α, CXCL10, IL-6, iNOS) mRNA expression when SIRT1 was inhibited.
Reversed the arjunolic acid-mediated upregulation of M2 marker (IL-10, Arg1, PPARγ) mRNA expression when SIRT1 was inhibited.

Cell Viability Assay

Cell Line: Saos-2 cells, U-2OS cells
Concentration: 0, 1, 5, 10, 25, 50,
and 100 μg/mL
Incubation Time: 24 h
Result: Reduced viability of Saos-2 cells in a concentration-dependent manner, reaching a plateau at 50 μg/mL.
Reduced viability of U-2OS cells in a concentration-dependent manner, reaching a plateau at 50 μg/mL.

Cell Viability Assay

Cell Line: H2O2-induced ARPE-19 cells
Concentration: 5 μM, 10 μM
Incubation Time: 24 h (co-treated with H2O2)
Result: Significantly increased the viability of H2O2-injured ARPE-19 cells, reversing the ~70% viability reduction caused by H2O2 alone.

Apoptosis Analysis

Cell Line: H2O2-induced ARPE-19 cells
Concentration: 5 μM, 10 μM
Incubation Time: 24 h (co-treated with H2O2)
Result: Reduced early apoptotic cells to 11.63% and total apoptotic cells to 13.43% at 5 μM.
Reduced early apoptotic cells to 9.03% and total apoptotic cells to 10.80% at 10 μM, compared to 21.53% early and 25.87% total apoptotic cells in H2O2-only cells.
Reduced the Bax/Bcl-2 ratio and cleaved-caspase-3 expression in H2O2-induced cells.

Cell Autophagy Assay

Cell Line: H2O2-induced ARPE-19 cells
Concentration: 5 μM, 10 μM
Incubation Time: 24 h (co-treated with H2O2)
Result: Significantly increased LC3-II/I protein ratio and LC3 immunofluorescence intensity at 5 μM and 10 μM.
Significantly reduced p62 protein expression at 5 μM and 10 μM.
Significantly increased p-AMPK protein levels to 1.01±0.09 and reduced p-mTOR protein levels to 0.254±0.05 at 10 μM compared to H2O2-only cells.
Pretreatment with AMPK inhibitor compound C reversed the arjunolic acid-induced increases in LC3 and HO-1, and blocked its anti-apoptotic effect.
体内研究
(In Vivo)

Arjunolic acid (25-50 mg/kg; p.o.; daily; 28 days) 可改善 Streptozotocin (MS-Q80520)-Nicotinamide (MS-T42892) 诱导的 2 型糖尿病大鼠的胰腺组织结构,下调炎症 (TLR-4/MyD88/NF-κB) 通路及经典 Wnt/β-catenin 信号通路,并恢复胰岛素信号标志物。
Arjunolic acid (80 mg/kg; p.o.; single) 可对 Acetaminophen (MS-H20928) 诱导的肝坏死提供完全的预处理保护,且即使在 8 小时后给药,也能提供显著的治疗后保护。
Arjunolic acid (50 mg/kg; two doses) 可通过维持抗氧化防御能力、减少炎症介质生成以及阻断半胱天冬酶依赖性细胞死亡通路,对 Acetaminophen 诱导的肾损伤发挥保护作用。
Arjunolic acid (25 mg/kg; every 2 days; 3 doses) 可通过清除活性氧并抑制 MAPK 介导的促凋亡信号通路,对抗 Doxorubicin (HY-15142A) 诱导的心肌细胞凋亡。
Arjunolic acid 可拮抗异丙肾上腺素诱导的心肌坏死,纠正心脏生物标志物异常与心电图异常,并抑制血小板聚集及凝血功能。
Arjunolic acid (20 mg/kg; daily; 4 days) 可通过维持抗氧化防御系统,抑制亚砷酸钠诱导的肝脏氧化损伤与坏死性肝损伤。
Arjunolic acid 可通过降低高血糖和高血脂、减轻血管炎症、抑制促凋亡信号通路以及维持心肌线粒体功能,对 Streptozotocin 诱导的糖尿病心肌病起到保护作用。
Arjunolic acid (10-100 mg/kg; single dose) 具有剂量依赖性抗炎活性,在 100 mg/kg 剂量下可抑制角叉菜胶诱导的大鼠足爪水肿达 80.8%(伴随胃肠道毒性),在 10 mg/kg 剂量下抑制率为 37.6%(无毒性)。
Arjunolic acid (10 mg/kg; single dose) 具有抗伤害感受活性,可将醋酸诱导的小鼠腹部收缩减少 30.3%。
Arjunolic acid 可抑制 Arachidonic acid (MS-A69140) 诱导的小鼠耳水肿,抑制率达 55.5%,表明其具有靶向环氧合酶介导的花生四烯酸代谢的活性。
Arjunolic acid (50-100 mg/kg; single dose) 具有剂量依赖性的肥大细胞稳定活性,可将 compound 48/80 诱导的大鼠肥大细胞脱颗粒作用在 50 mg/kg 剂量下降至 42%,在 100 mg/kg 剂量下降至 33%。
Arjunolic acid (50-100 mg/kg; single dose) 具有剂量依赖性的抗哮喘活性,在 100 mg/kg 剂量下可保护豚鼠免受组胺诱导的支气管痉挛,保护率最高达 64%,免受乙酰胆碱诱导的支气管痉挛的保护率最高达 51%。
Arjunolic acid (1% topical ointment) 可促进大鼠皮肤伤口愈合,在第 20 天实现完全上皮化。
Arjunolic acid (10-40 mg/kg; i.g.; daily; 7 days) 可通过促进小胶质细胞 M2 极化、提高海马体 BDNF 和 5-HT 水平并激活 SIRT1/AMPK/Notch1 信号通路,显著改善雄性 C57BL/6 小鼠中 LPS 诱导的抑郁样行为。
Arjunolic acid (15-60 mg/kg; p.o.; daily; 28 days) 可通过改善肠道屏障功能、抑制肠道上皮细胞凋亡 (机制为下调 TLR4/MyD88 通路) 以及恢复有益肠道菌群组成和短链脂肪酸生成,缓解 Il-10-/- 小鼠的自发性克罗恩病样结肠炎。
Arjunolic acid (100 mg/kg; p.o.; once daily; 21bdays) 可通过下调 Wnt3a,减少肿瘤增殖、促进肿瘤细胞凋亡,并将肿瘤相关巨噬细胞的极化方向从促肿瘤的 M2 型转向抗肿瘤的 M1 型,从而抑制裸鼠体内骨肉瘤的进展与转移。
Arjunolic acid (10-30 mg/kg; p.o.; once daily; 10 weeks) 可通过降低空腹血糖、增加体重、维持视网膜结构、抑制视网膜细胞凋亡与炎症反应、上调 HO-1 并激活 AMPK/mTOR 调控的自噬通路,改善Streptozotocin (MS-Q80520) 诱导的大鼠糖尿病视网膜病变。
Arjunolic acid (1.0-2.0 mg/kg; p.o.; daily; 4 weeks) 可通过抑制氧化炎症应激和细胞凋亡逆转 Fluoxetine (MS-Y34805) 诱导的雄性 Wistar 大鼠睾丸功能障碍,其中 2.0 mg/kg 灌胃剂量的抗炎效力优于 1.0 mg/kg 剂量。

Animal Model: Sprague Dawley (male, 8-10 weeks old, 250-300 g, streptozotocin-nicotinamide induced T2DM)
Dosage: 25 mg/kg; 50 mg/kg
Administration: p.o.; daily; 28 days
Result: Alleviated islet degeneration at a dose of 25 mg/kg; at a dose of 50 mg/kg, it significantly ameliorated islet atrophy, apoptosis, necrosis, karyolysis, and vacuolization, restored the typical arrangement of pancreatic acinar cells, completely eliminated the collagen matrix, and restored a nearly normal islet morphology.
It improved islet size and number, and downregulated the expression of NF-κB, p-JNK1/2, Wnt3a, and β-catenin proteins; notably, the expression of MyD88 protein was significantly downregulated only at the 50 mg/kg dose.
Reduced the localization of TLR-4, NF-κB, and p-JNK1/2; significantly reduced the localization of Wnt3a and β-catenin; and, only at the 50 mg/kg dose, significantly increased the localization of IRS-1.
Significantly downregulated the mRNA expression of MyD88 and NF-κB; significantly downregulated the mRNA expression of β-catenin; and, only at the 50 mg/kg dose, significantly downregulated the mRNA expression of TNF-α, IL-1β, and Wnt3a.
Animal Model: Rats (acetaminophen-induced liver toxicity model)
Dosage: 80 mg/kg
Administration: p.o.; single dose
Result: Prevented acetaminophen-induced hepatic glutathione depletion, formation of the reactive acetaminophen metabolite NAPQI, centrilobular liver necrosis, and maintained liver histology near normal.
Reduced JNK activation, phosphorylation of antiapoptotic Bcl-2 and Bcl-xL, mitochondrial permeabilization, loss of mitochondrial membrane potential, and cytochrome c release when administered 4 hours after acetaminophen exposure.
Attenuated liver injury to a degree similar to the 4-hour post-treatment group when administered 8 hours after acetaminophen exposure.
Animal Model: C57BL/6 (male, 20-23 g, LPS-induced depressive behavior)
Dosage: 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: i.g.; daily; 7 days
Result: Significantly reduced the immobility time in both the tail suspension test and the forced swim test, and significantly increased sucrose preference.
Inhibited LPS-induced nuclear shrinkage of hippocampal neurons and elevated hippocampal BDNF protein levels; compared to the LPS + vehicle group, the 40 mg/kg dose group significantly increased hippocampal 5-HT levels.
Reduced the number of iNOS+IBA1+ (M1-type) microglia in the mouse hippocampus and increased the number of Arg1+IBA1+ (M2-type) microglia.
Significantly enhanced the expression levels and activity of hippocampal SIRT1 protein, significantly increased phosphorylated AMPK (p-AMPK) protein levels, and significantly reduced the expression levels of Notch1 protein.
Animal Model: C57BL/6J Il-10-/- (male, 15 weeks old, spontaneous colitis); C57BL/6J wild-type (male, 15 weeks old)
Dosage: 15 mg/kg; 30 mg/kg; 60 mg/kg
Administration: p.o.; daily; 28 days
Result: Reduced weight loss.
Decreased disease activity index scores.
Increased colon length.
Lowered colonic inflammation scores.
Reduced colonic tissue levels of IL-1β, IL-6, and TNF-α.
Decreased serum FITC-dextran levels.
Increased colonic transepithelial electric resistance values.
Reduced bacterial translocation rates in liver, mesentery lymph nodes, and spleen of Il-10-/- mice.
Increased intestinal expression of tight junction proteins ZO-1 and Claudin-1.
Reduced the percentage of TUNEL-positive colonic epithelial cells.
Upregulated colonic Bcl2 protein levels.
Downregulated colonic Bax and C-caspase-3 protein levels.
Suppressed colonic TLR4 and MyD88 protein expression.
Increased fecal levels of acetate, propionate, and butyrat.
Reduced serum LPS levels.
Elevated fecal Ruminococcus abundance.
Decreased fecal Bacteroidetes, Bacteroidia, and Bacteroidales abundance.
Reduced weight loss in recipient Il-10-/- mice via fecal microbial transplantation from treated mice.
Decreased disease activity index scores in recipient Il-10-/- mice via fecal microbial transplantation from treated mice.
Increased colon length in recipient Il-10-/- mice via fecal microbial transplantation from treated mice.
Lowered colonic IL-1β, IL-6, and TNF-α levels in recipient Il-10-/- mice via fecal microbial transplantation from treated mice.
Decreased serum FITC-dextran levels in recipient Il-10-/- mice via fecal microbial transplantation from treated mice.
Increased colonic transepithelial electric resistance values in recipient Il-10-/- mice via fecal microbial transplantation from treated mice.
Reduced serum 16S rDNA levels in recipient Il-10-/- mice via fecal microbial transplantation from treated mice.
Animal Model: nude mice (5-week-old, male)
Dosage: 100 mg/kg
Administration: p.o.; once daily; 21 consecutive days
Result: Reduced tumor volume and tumor mass significantly.
Decreased Ki67 positive rate from ~20% to ~12%.
Decreased expression of cell cycle proteins CDK2, CDK4, and Cyclin D1.
Increased tumor cell apoptosis rate from ~10% to ~20%.
Reduced number of lung metastatic nodules from ~10 to ~4.
Decreased M2 macrophage markers: reduced CD163 positive cells from ~51% to ~21%; significantly decreased Arg-1, IL-10, TGF-β1, MMP-9 mRNA and serum protein levels.
Increased M1 macrophage markers: increased CD86 positive cells from ~30% to ~61%; significantly increased IL-6, IL-1β, TNF-α, iNOS mRNA and serum protein levels.
Reduced tumor Wnt3a mRNA expression significantly.\nIn combination with Wnt3a knockdown, further reduced tumor volume and mass, enhanced tumor tissue damage, decreased Ki67, CDK2, CDK4, and Cyclin D1 expression, increased tumor cell apoptosis, reduced lung metastatic nodules, further suppressed M2 macrophage markers, and further increased M1 macrophage markers compared to arjunolic acid alone.
In combination with Wnt3a overexpression, reversed anti-tumor effects: increased tumor volume and mass, exacerbated tumor tissue pathology, increased Ki67, CDK2, CDK4, and Cyclin D1 expression, decreased tumor cell apoptosis, increased lung metastatic nodules, upregulated M2 macrophage markers, and downregulated M1 macrophage markers.
Animal Model: Sprague-Dawley (male, 180-200 g, diabetic retinopathy induced by 65 mg/kg STZ i.p. injection)
Dosage: 10 mg/kg; 30 mg/kg
Administration: p.o.; once daily; 10 weeks
Result: Reduced fast blood glucose to 17.5 mmol/L (10 mg/kg) and 14.7 mmol/L (30 mg/kg) from 30.4 mmol/L in the STZ-only group.
Significantly increased final body weight compared to the STZ-only group for both doses.
Increased retinal outer nuclear layer (ONL) thickness to ~28 μm (10 mg/kg) and ~35 μm (30 mg/kg) from ~18 μm in the STZ-only group; significantly elevated ONL nuclei counts.
Reduced TUNEL-positive retinal cell area by 32% (10 mg/kg) and 70% (30 mg/kg) compared to the STZ-only group.
Decreased Bax/Bcl-2 protein ratio to ~2.8 (10 mg/kg) and ~2.0 (30 mg/kg) from ~4.0 in the STZ-only group; significantly reduced cleaved caspase-3 protein levels.
Significantly reduced retinal levels of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α for both doses; 30 mg/kg dose showed for IL-6 and TNF-α, and for IL-1β compared to the STZ-only group.
Significantly upregulated retinal HO-1 protein expression in the 30 mg/kg dose group.
Significantly increased LC3-II/I protein ratio, significantly reduced p62 protein levels, upregulated AMPK phosphorylation, and downregulated mTOR phosphorylation in treated groups compared to the STZ-only group.
Animal Model: Wistar rats (male, 6-8 weeks old, 150-250 g, testicular dysfunction induced by oral fluoxetine 10 mg/kg daily for 4 weeks)
Dosage: 1.0 mg/kg; 2.0 mg/kg; 1.0 mg/kg (co-administered with fluoxetine); 2.0 mg/kg (co-administered with fluoxetine)
Administration: p.o.; daily; 4 weeks
Result: Significantly reversed fluoxetine-induced alterations when co-administered at 1.0 mg/kg and 2.0 mg/kg, including reduced testicular MDA levels, increased SOD, CAT, and GSH activities, decreased TNF-α, IL-1ß, and MPO levels, normalized Bcl-2, p53, and caspase-3 levels, restored 3ß-HSD and 17ß-HSD activities, and recovered Na+/K+ ATPase, Ca2+ ATPase, and H+ ATPase activities.
Showed more significant inflammatory marker reduction effects at 2.0 mg/kg than at 1.0 mg/kg when co-administered with fluoxetine.
Repaired fluoxetine-induced testicular histopathological damage, including degenerated seminiferous tubules, necrosis, atrophy, pyknotic cells, vascular congestion, and disrupted spermatogenesis, restoring near-normal testicular architecture when co-administered at 1.0 mg/kg and 2.0 mg/kg.
性状 固体
颜色 White to off-white

化学信息

分子量 488.70
分子式 C30H48O5
CAS No. 465-00-9
别名 阿江榄仁酸; 阿酚酸

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.09 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (204.62 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.0462 mL10.2312 mL20.4625 mL51.1561 mL
5 mM0.4092 mL2.0462 mL4.0925 mL10.2312 mL
10 mM0.2046 mL1.0231 mL2.0462 mL5.1156 mL
15 mM0.1364 mL0.6821 mL1.3642 mL3.4104 mL
20 mM0.1023 mL0.5116 mL1.0231 mL2.5578 mL
25 mM0.0818 mL0.4092 mL0.8185 mL2.0462 mL
30 mM0.0682 mL0.3410 mL0.6821 mL1.7052 mL
40 mM0.0512 mL0.2558 mL0.5116 mL1.2789 mL
50 mM0.0409 mL0.2046 mL0.4092 mL1.0231 mL
60 mM0.0341 mL0.1705 mL0.3410 mL0.8526 mL
80 mM0.0256 mL0.1279 mL0.2558 mL0.6395 mL
100 mM0.0205 mL0.1023 mL0.2046 mL0.5116 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

阿江榄仁酸;阿酚酸 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础